CRISM Therapeutics Corporation (LSE:CRTX), the AIM-quoted developer of a localised chemotherapy implant for brain cancer, has moved into a new phase of its development. The company has announced that patient recruitment has begun in its Phase II clinical trial in glioblastoma, following the activation of the first clinical site, and it has set the date for its annual general meeting. Coming after a US regulatory milestone earlier in the year, the news has kept the small-cap biotech on the radar of investors who follow the FTSE AIM All Share Index.

What the Company Does

CRISM is focused on ChemoSeed, a technology designed to deliver chemotherapy directly into the brain. Its lead programme places implants containing the established cancer drug irinotecan into the cavity left after surgical removal of a tumour, with the aim of treating residual cancer cells locally while limiting the side effects associated with conventional systemic chemotherapy. The NHS Health Research Authority lists a study of irinotecan-ChemoSeed in surgically resectable glioblastoma, the most common and aggressive primary brain cancer in adults. The company trades on AIM under the ticker CRTX.

Latest Developments

The most significant recent milestone is the start of the Phase II trial. CRISM reported the activation of its first clinical site and the opening of patient recruitment, marking the move from regulatory preparation into active clinical work. The company had announced approval for a UK Phase II clinical trial in September 2025, when CRISM gained clearance for the study.

In March 2026, the US Food and Drug Administration granted Orphan Drug designation to the company's irinotecan delivery implant for high-grade glioma. CRISM shares jumped 12% following the news. Orphan designation is intended to encourage development of therapies for rare conditions and can bring benefits such as a period of market exclusivity if a product is eventually approved.

Corporate Activity

Alongside the clinical news, CRISM has issued a number of corporate announcements in 2026. These include a notice of general meeting, a grant of share options, the result of a Shareholder analysis and, most recently, a notice of its annual general meeting. The company has also announced the appointment of a non-executive chair. Specific details of the option grant and the general meeting resolutions were not set out at the time of writing.

Financial Picture

As a clinical-stage company, CRISM does not generate product Revenue and relies on its cash reserves and Capital raised from investors to fund research. It has published interim results, but detailed cash and loss figures were not captured at the time of writing, so none are quoted here. No Dividend is paid, which is normal for a development-stage biotech.

Sector and index Context

Glioblastoma remains an area of high unmet medical need, with limited treatment Options and poor long-term survival rates, which has attracted interest in new delivery approaches. CRISM sits among a cluster of small AIM-listed life sciences companies within the FTSE AIM All Share Index, where valuations are often driven by trial milestones and funding news rather than earnings.

Key Risks

The main risks are clinical and financial. The Phase II trial may not produce positive results, recruitment could take longer than planned, and regulatory pathways can change. The company is likely to need further funding to progress development, which could dilute existing shareholders. Share prices of small biotechs can also be highly volatile.

What to Watch Next

Investors will be watching for progress in recruitment, the activation of further trial sites, any early safety observations, the outcome of the Annual General Meeting and updates on the company's cash runway and funding plans.